Anti-Müllerian hormone in premenopausal women following treatment of uterine cervical cancer.

• In this longitudinal study we prospectively enrolled 32 premenopausal women (ages 23-44years) with stage I-III uterine cervical cancer undergoing surgery and/or chemoradiation. Serum levels of anti-Müllerian hormone, follicle-stimulating hormone and estradiol were examined at baseline and 1year after treatment. As expected, serum anti-Müllerian hormone was undetectable after salpingo-oophorectomy or chemoradiation. After radical hysterectomy and pelvic lymphadenectomy with ovarian preservation serum anti-Müllerian hormone declined from a mean value of 2.0±1.4μg/L to 1.1±0.8μg/L (p=0.01), representing a 45% reduction, whereas there was no significant change in serum levels of follicle-stimulating hormone and estradiol. This implies that ovarian function may be affected not only by castrating treatment but also by radical hysterectomy with ovarian preservation. The risk of premature menopause and the potential need of hormone replacement therapy among these women may be overlooked since they no longer menstruate.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Reproduktionsmedicin och gynekologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Obstetrics, Gynaecology and Reproductive Medicine (hsv//eng)

Nyckelord

Adult

Anti-Mullerian Hormone

blood

Antineoplastic Agents

therapeutic use

Estradiol

blood

Female

Follicle Stimulating Hormone

blood

Humans

Hysterectomy

Longitudinal Studies

Middle Aged

Prospective Studies

Salpingectomy

Treatment Outcome

Uterine Cervical Neoplasms

blood

drug therapy

surgery

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)